

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * <u>INVESTOR AB</u> (Last) (First) (Middle) <u>C/O INVESTOR GROWTH CAPITAL, LLC</u> <u>ONE ROCKEFELLER PLAZA, SUITE</u> <u>2801</u> (Street) <u>NEW YORK NY 10020</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>05/22/2014</u>	3. Issuer Name and Ticker or Trading Symbol <u>AGILE THERAPEUTICS INC [AGRX]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
Series B Preferred Stock	05/22/2014	(3)	Common Stock 1,950,200	(3)	I	See Footnotes ⁽¹⁾⁽²⁾
Series C Preferred Stock	05/22/2014	(4)	Common Stock 424,557	(4)	I	See Footnotes ⁽¹⁾⁽²⁾
Convertible Promissory Notes	05/22/2014	(5)	Common Stock 135,192	(5)	I	See Footnotes ⁽¹⁾⁽²⁾

Explanation of Responses:

- As of May 22, 2014 (the "Effective Date"), certain affiliated entities of Investor AB, a publicly held Swedish company (the "Reporting Person"), hold the securities set forth in Table II above of Agile Therapeutics, Inc., a Delaware corporation (the "Issuer"). As a result of the foregoing, as of the Effective Date, the Reporting Person possesses the sole power to vote and the sole power to direct the disposition of the securities of the Issuer set forth in Table II above.
- The Reporting Person's interest in the securities of the Issuer set forth in Table II above reported herein is limited to its pecuniary interest, if any, in such securities.
- The Issuer's Series B Preferred Stock is convertible by the Reporting Person at any time on a 1.4-for-1 basis and will automatically convert into shares of Common Stock on a 1.4-for-1 basis upon the closing of the Issuer's initial public offering and has no expiration date.
- The Issuer's Series C Preferred Stock is convertible by the Reporting Person at any time on a 1.4-for-1 basis and will automatically convert into shares of Common Stock on a 1.4-for-1 basis upon the closing of the Issuer's initial public offering and has no expiration date.
- The Issuer's 8% Convertible Promissory Notes (the "Notes") will automatically convert upon the closing of the Issuer's initial public offering into a number of shares of Common Stock equal to the quotient of the aggregate outstanding principal amount and all accrued and unpaid interest due under the Notes divided by the initial public offering price, which is \$6.00 per share of Common Stock.

Investor AB By: /s/ Michael V. Oporto, Authorized Signatory 05/22/2014

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.